130 related articles for article (PubMed ID: 38517344)
1. CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.
Hu J; Xu Y
J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
[TBL] [Abstract][Full Text] [Related]
2. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
4. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
Bouchal J; Santer FR; Höschele PP; Tomastikova E; Neuwirt H; Culig Z
Prostate; 2011 Mar; 71(4):431-7. PubMed ID: 20859991
[TBL] [Abstract][Full Text] [Related]
8. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses.
Yu J; de Belle I; Liang H; Adamson ED
Mol Cell; 2004 Jul; 15(1):83-94. PubMed ID: 15225550
[TBL] [Abstract][Full Text] [Related]
9. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
10. CREB-binding protein/p300 are transcriptional coactivators of p65.
Gerritsen ME; Williams AJ; Neish AS; Moore S; Shi Y; Collins T
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2927-32. PubMed ID: 9096323
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300.
Papoutsopoulou S; Janknecht R
Mol Cell Biol; 2000 Oct; 20(19):7300-10. PubMed ID: 10982847
[TBL] [Abstract][Full Text] [Related]
12. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
14. p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint.
Stauffer D; Chang B; Huang J; Dunn A; Thayer M
J Biol Chem; 2007 Mar; 282(13):9678-9687. PubMed ID: 17272271
[TBL] [Abstract][Full Text] [Related]
15. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation.
Kasper LH; Lerach S; Wang J; Wu S; Jeevan T; Brindle PK
EMBO J; 2010 Nov; 29(21):3660-72. PubMed ID: 20859256
[TBL] [Abstract][Full Text] [Related]
16. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions.
Yang C; Shapiro LH; Rivera M; Kumar A; Brindle PK
Mol Cell Biol; 1998 Apr; 18(4):2218-29. PubMed ID: 9528793
[TBL] [Abstract][Full Text] [Related]
17. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M; Lazarova DL
World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
[TBL] [Abstract][Full Text] [Related]
18. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells.
Ianculescu I; Wu DY; Siegmund KD; Stallcup MR
J Biol Chem; 2012 Feb; 287(6):4000-13. PubMed ID: 22174411
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional coactivators CBP and p300 cooperatively enhance HNF-1alpha-mediated expression of the albumin gene in hepatocytes.
Dohda T; Kaneoka H; Inayoshi Y; Kamihira M; Miyake K; Iijima S
J Biochem; 2004 Sep; 136(3):313-9. PubMed ID: 15598887
[TBL] [Abstract][Full Text] [Related]
20. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells.
Xu W; Fukuyama T; Ney PA; Wang D; Rehg J; Boyd K; van Deursen JM; Brindle PK
Blood; 2006 Jun; 107(11):4407-16. PubMed ID: 16424387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
